DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Squamous Cell Carcinoma of the Head and Neck – Epidemiology – Extrapolated worldwide coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key squamous cell carcinoma of the head and neck patient populations,…
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2024
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic Squamous Non-Small-Cell Lung Cancer (US/EU)
With only a small percentage of patients harboring a biomarker-driven metastatic squamous non-small-cell lung cancer (NSCLC) (about 10% of all patients in the G7 countries), the preferred first-…
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2023
The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…
Non-Small-Cell Lung Cancer | Unmet Need | EGFR-Mutation-Positive Metastatic Nonsquamous NSCLC | US/EU5 | 2023
Approximately 20% of Western patients with nonsquamous NSCLC present with EGFR mutations, creating a market for targeted and personalized treatments. Although the market for EGFR-mutation-positive…
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2022
The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…
